三上悠亚久久精品,少妇spa推油被扣高潮,波多野结av衣东京热无码专区,亚洲乱码中文字幕久久孕妇黑人

NKF's subsidiary Kindos's Idarubicin Hydrochloride Injection gets FDA approval for marketing

Continue to promote high-quality products and services to a new level

2025-05-26

Learn more +
NKF's subsidiary Kindos's Mitoxantrone Injection gets FDA approval for marketing

Another quick approval

2025-05-22

Learn more +
Paclitaxel For Injection (Albumin Bound) approved by US FDA

2025-05-20

Learn more +
King-Friend will meet you in CPHI Frankfurt!

Explore the infinite boundaries of the pharmaceutical market！

2025-05-19

Learn more +
King-Friend will meet you in CPHI Shanghai!

Explore the infinite possibilities of the pharmaceutical industry！

2025-05-13

Learn more +
NKF's Liraglutide Injection gets FDA approval for marketing

Benefiting more patients around the world.

2025-04-04

Learn more +
NKF's Rocuronium Bromide Injection getting approved by NMPA

Bring new hope for health to thousands of patients.

2025-03-01

Learn more +
NKF's Fulvestrant Injection getting approved by NMPA

Help to enhance treatment experience and health well-being.

2025-02-11

Learn more +
NKF's Methylene Blue Injection gets FDA approval for marketing

Let every medication be a solemn commitment to life.

2025-01-25

Learn more +

1
2

Stock price

11.160

-0.029999999999999

?2025 Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd蘇ICP備13012010號(hào)

<cite id="a0ae0"></cite><samp id="a0ae0"></samp>